Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics (Nasdaq: EWTX) announced inducement grants on February 27, 2026, issuing options to purchase 51,000 shares to three new non-executive employees under its 2024 Inducement Equity Incentive Plan.

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) announced inducement grants on February 27, 2026, issuing options to purchase 51,000 shares to three new non-executive employees under its 2024 Inducement Equity Incentive Plan.

Options carry an exercise price of $30.44 equal to the closing price on the grant date and vest 25% after one year then monthly at 1/48th thereafter, subject to continued service, granted under Nasdaq Listing Rule 5635(c)(4).

Argus Mar 2 session

-2.43% close to close Open Argus

Details

News Market Reaction – EWTX

On Mar 2, the day this news came out, EWTX closed 2.43% below the previous close.

Data tracked by StockTitan Argus for the Mar 2 session.

Key Figures

Inducement options granted: 51,000 shares Number of employees: 3 employees Option exercise price: $30.44 per share +3 more

Inducement options granted

51,000 shares

Stock options to 3 new non-executive employees

Number of employees

3 employees

Recipients of inducement stock options

Option exercise price

$30.44 per share

Equal to closing price on February 27, 2026 grant date

Initial vesting

25%

Vests on one-year anniversary of each employee’s start date

Ongoing vesting fraction

1/48th monthly

Additional vesting each month after first year, contingent on service

Nasdaq rule

Rule 5635(c)(4)

Inducement awards granted in reliance on this listing rule

Historical Context

5 past events · Latest: Feb 26

5 events

1. Feb 26

   Earnings results

   24h Move

   -1.5%

   Q4 and 2025 results with $530.1M cash and pipeline milestones.

2. Feb 05

   Conference presentation

   24h Move

   -4.5%

   Announcement of presentation at Guggenheim Emerging Outlook Biotech Summit.

3. Feb 02

   Inducement grants

   24h Move

   +2.6%

   Inducement options for seven new employees under 2024 Inducement Plan.

4. Jan 13

   Corporate update

   24h Move

   +3.4%

   2026 priorities, pivotal GRAND CANYON plans and April 2025 financing use.

5. Jan 06

   Conference announcement

   24h Move

   -2.7%

   Planned J.P. Morgan Healthcare Conference presentation webcast details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

inducement stock options, nasdaq listing rule 5635(c)(4)

2 terms

inducement stock options financial

"Edgewise granted inducement stock options to purchase a total of 51,000 shares..."

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

nasdaq listing rule 5635(c)(4) regulatory

"...material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, Colo., March 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on February 27, 2026, Edgewise granted inducement stock options to purchase a total of 51,000 shares of Edgewise's common stock to 3 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").

Each inducement stock option has an exercise price of $30.44 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4).

About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn and X.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302701086.html

SOURCE Edgewise Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Edgewise (EWTX) grant as inducement awards on February 27, 2026?

Edgewise granted inducement options covering 51,000 shares to three new non-executive employees. According to the company, the awards were issued under the 2024 Inducement Equity Incentive Plan as recruitment inducements.

What is the exercise price of the inducement options Edgewise (EWTX) granted in February 2026?

Each inducement option has an exercise price of $30.44 per share, equal to the closing price on the grant date. According to the company, that price matches the market close on the grant date and applies to all grants.

What vesting schedule applies to Edgewise (EWTX) inducement stock options granted February 27, 2026?

The options vest 25% on the one-year anniversary and then monthly at 1/48th thereafter, subject to continued service. According to the company, this schedule applies to each employee's start date.

Were Edgewise (EWTX) inducement grants made under a Nasdaq rule, and which one?

Yes, the grants were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4). According to the company, the awards were granted as material inducements to commence employment.

Who received the inducement awards from Edgewise (EWTX) and under which plan were they granted?

Three new non-executive employees received the inducement options under Edgewise's 2024 Inducement Equity Incentive Plan. According to the company, the grants were tied to the commencement of each employee's employment.